Chief Strategy Officer and Board Director
Dr. Jiang is responsible for XtalPi’s strategy development including identification of growth opportunities, strategic planning and execution. He joined XtalPi in 2015 bringing over fifteen years of scientific and research management experience, most of it gained in positions of increasing responsibility at Genzyme and Sanofi-Genzyme. His early tenure at Genzyme was in disease biology research focused on oncology and genetic diseases. Following Sanofi’s acquisition of Genzyme in 2011, Dr. Jiang was appointed as liaison and director of Asia R&D Strategy of the Sanofi-Genzyme R&D Center. In that capacity he was responsible for the development of Genzyme Asia/China R&D strategy and led cross-functional R&D external collaborations and projects in Asia. He was also a key member of the Translational Medicine team and focused on strategic implementation of pharmacogenomics and biomarker in early clinical development.
Alan received his medical degree and doctorate in molecular biology followed by post-doctoral research in hematology and oncology at Brigham & Women’s Hospital, Harvard Medical School. Dr. Jiang earned his Ph.D. in molecular biology from University of Tennessee-Health Science Center and M.D. from Shanghai Medical University (now Shanghai Medical College of Fudan University).
Our keynote panelists will share their views on the emerging intersection of healthcare and AI and how AI will impact various areas of the market, including drug discovery, diagnostic imaging, and management of patient outcomes. The session will also focus on innovations seen in the delivery of healthcare with access to better technology and data.